Please Wait...

IGFBP-3 // Insulin-Like Growth Factor Binding Protein 3

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

The majority of Insulin Like Growth Factors (IGFs) in serum is complexed with IGF Binding Proteins (IGFBP) and acid-labile subunit (ALS). Six IGFBPs have been cloned and identified. IGFBP3 has the highest binding capacity for IGF-1 and it prolonged its high life in serum. GFBPs in serum regulate the endocrine actions of IGFs by modulating bioavailable IGF (Mohan and Baylink, 2002). IGFBPs constitute a "buffer" capable of limiting the effect of a rise in IGF concentration (which could result in hypoglycemia) (Ranke, 2015). IGFBP3, through its binding with IGF-1, can also have a role in cancer cell growth and proliferation through a possible potentiation of IGF-1 signaling (Baxter, 2014).

Bioclinica Lab employs a high sensitive manual sandwich immunoassay for measurement of IGFBP3 in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen